A new experimental drug aimed at extending the lifespan of pet dogs has sparked widespread discussion online, drawing both excitement and skepticism. The pill, named LOY-002, has been developed by biotech company Loyal and is currently undergoing clinical trials in the United States.
The drug is being tested on nearly 1,300 senior dogs across multiple veterinary clinics. Early findings suggest that it may help increase a dog’s healthy lifespan by at least a year. However, researchers have emphasized that the trials are still ongoing and conclusive results are yet to be confirmed.
Scientists have long observed that dogs on calorie-restricted diets tend to live longer and develop age-related diseases later. LOY-002 aims to mimic those benefits without reducing the dog’s food intake, allowing pets to maintain their usual diet while potentially slowing the ageing process.
The development quickly gained traction on social media after going viral, with millions engaging in the conversation. Many pet owners expressed hope and excitement at the possibility of spending more time with their beloved animals. Some users shared emotional responses, saying they would “give anything for one more year” with their pets.
At the same time, others raised concerns about the scientific validity and intent behind the drug. Questions around whether it is a genuine breakthrough or a commercial attempt to capitalize on pet owners’ emotions have surfaced. Some also pointed out the irony of developing lifespan-extending treatments for animals while similar solutions for humans remain limited.
While the drug is still under regulatory review, it has undoubtedly ignited a broader conversation about ageing, pet care, and the ethical implications of extending life through science.